Some founders start and develop a company throughout their careers. From Dr. Arokiaswamy Velumani, a Thyrocare founder, we learn how he created one of the largest diagnostic chains in India out of a thyroid lab, partially funded by his provident fund savings, sold a significant stake in the company at its peak, invested the money, and eventually admitted to losing a substantial amount. 

In this regard, the biographical information of Dr. Arokiaswamy Velumani is perhaps one of the most surprising net-worth stories compared to public perception regarding wealth building and management. Moreover, it is interesting to follow both his successes and failures, as he was open about them.

This article includes information regarding Dr. Arokiaswamy Velumani’s net worth, biographical data, professional history, and an in-depth look at Thyrocare’s creation based on facts, comparisons, and open answers to questions that arise after reading.

Quick Overview

Detail	Information
Full Name	Dr. Arokiaswamy Velumani
Date of Birth	April 12, 1959
Birthplace	Appanaickenpatti Pudur, near Coimbatore, Tamil Nadu, India
Education	B.Sc. (University of Madras); M.Sc.; Ph.D. in Biochemistry (University of Mumbai)
Occupation	Entrepreneur, Scientist, Founder of Thyrocare Technologies; Founder & MD, Nueclear Healthcare
Known For	Founding Thyrocare, one of the world’s largest thyroid and diagnostic testing chains
Previous Career	14 years as a scientist at the Bhabha Atomic Research Centre (BARC)
Late Wife	Sumathi Velumani, married 1986; passed away in February 2016
Children	Anand Velumani (born 1989) and Amruta Velumani (born 1991)
Major Business Event	Sold his 66.1% stake in Thyrocare to PharmEasy’s parent, API Holdings, for ₹4,546 crore in 2021
Estimated Net Worth	Reported estimates suggest over ₹5,000 crore (~$600 million), though this is not officially confirmed

Who is Arokiaswamy Velumani?

Dr. Arokiaswamy Velumani, also known as Arun, is an Indian business magnate and scientist who has founded the Thyrocare Technologies diagnostic and preventive healthcare chain. He was born into a landless agricultural family in Coimbatore, Tamil Nadu. 

Image Courtesy: velumani / Official Website

After working for 14 years at the Bhabha Atomic Research Centre, investigating the endocrine system using radioimmunoassay, he left BARC in 1995 to establish his own medical diagnostics company. He used approximately one lakh rupees from his provident fund to found Thyrocare in 1996 and began franchising the concept. 

He took the firm public in 2016 and sold a majority stake to API Holdings, the parent company of PharmEasy, in 2021, walking away from the business as well as his riches for the last decade.

Arokiaswamy Velumani Net Worth

Dr. Velumani has never openly shared his net worth, and, unlike many founder-CEOs whose shareholding in the company rarely changes for decades, his wealth has undergone several significant transformations during his professional career. 

As of now, various financial analysts and biographers estimate his net worth at over 5,000 crore rupees (approximately $600 million), although this information is not considered reliable since the doctor only shares details of his transactions about which he publicly expresses his satisfaction.

A Series of Significant Profit Fluctuations for Velumani

Period	Reported Value or Description	Event
2011	Thyrocare worth approx. ₹600 crore; ~64% belongs to Velumani, who owns ~2,062 crore	The company goes public
2016	Thyrocare stake worth ~₹5,000 crore; the company is estimated at ~₹7,000 crore	Velumani’s wife Sumathi passes away in February 2016
June 2021	66.1% of Thyrocare sold for ₹4,546 crore	The stake is sold to PharmEasy’s parent company API Holdings, and ₹1,500 crore from the proceeds are reinvested in API Holdings (reportedly, ~5%)
February 2024	Loss of ₹1,400 crore reported on social media	The investment in API/PharmEasy is described as “greedy and blinded” by the investor
Recent reports	Over ₹5,000 crore (unconfirmed)	The net worth is estimated to comprise the remaining API Holdings stake, Nueclear Healthcare, and other assets

This series of transactions underscores that, regarding Dr. Velumani’s net worth, one should consider not only the steady increase but also the significant drawdown the doctor admitted in 2024. 

Perhaps, in part because of this, few prominent entrepreneurs have been as open about their investments as Velumani, who directly acknowledged the error in purchasing API Holdings shares. At the same time, this factor must be considered when evaluating the reliability of the reported profitability of Thyrocare.

Sources of Wealth for Arokiaswamy Velumani

• Proceeds from the sale of Thyrocare stake in 2021: the single largest source of the doctor’s wealth, which amounts to 4,546 crore as of June 2021.
• The remaining shares in API Holdings (PharmEasy), which comprise about 5%: 1,500 crore were purchased with the proceeds of the Thyrocare stake.
• Nueclear Healthcare Limited: a diagnostic radiology company, a significant part of the profits of which are used for charitable purposes. Velumani is the founder and managing director of the company; it provides cancer screening at reduced prices.
• Personal investments, both charitable and business-related: the doctor has been open about his investments in various companies and the allocation of significant personal funds to philanthropy and charities. In particular, he has repeatedly donated to Thyrocare’s CSR programs.

Early Life and Education

Arokiaswamy Velumani was born on April 12, 1959, in Appanaickenpatti Pudur, a small village near Coimbatore, Tamil Nadu, into a family with no land of its own. 

His father worked as a farmer, and his mother supported the family by rearing buffaloes and selling their milk, often managing to put together only a modest amount each week to sustain the household. Velumani has spoken candidly about the hardship of his early years, including days without enough food and long walks to attend school.

He completed his early education at Sri Venkateswara High School in his home village before earning a Bachelor of Science degree in Chemistry from the University of Madras in 1978. His first job was as a shift chemist at Gemini Capsules, a small pharmaceutical company in Coimbatore, earning approximately ₹150 per month. 

After the company shut down, Velumani found himself unemployed and, with very limited money in hand, made the decision to move to Mumbai in search of better opportunities — a period he has described as involving real financial desperation, including nights spent at a railway station before he found stable footing. He went on to complete a Master’s degree and later earned a Ph.D. in Biochemistry from the University of Mumbai.

Career Journey: From BARC Scientist to Diagnostics Pioneer

Fourteen Years at BARC (1981–1995)

Velumani joined the Bhabha Atomic Research Centre (BARC) as a scientist, where he spent 14 years conducting research related to thyroid disorders using radioimmunoassay technology — a highly technical field that directly shaped his understanding of diagnostic testing. 

This period gave him both deep scientific expertise and, eventually, the specific insight that affordable thyroid testing was a genuine, underserved market need in India.

Founding Thyrocare (1995–1996)

Image Courtesy: Thyrocare / Official Website

In 1995, Velumani left his stable government research position to pursue entrepreneurship, using roughly ₹1 lakh from his provident fund to start his own venture. In 1996, he formally established Thyrocare, a thyroid testing laboratory in Mumbai. 

His wife, Sumathi, who had been working at the State Bank of India, left her own job to join him as the company’s first employee — a partnership Velumani has repeatedly credited as foundational to the business’s success, describing her as having taken on roughly 25% of the company’s business responsibilities as a co-founder, alongside the vast majority of the couple’s non-business responsibilities.

Building a Franchise-Based, Affordable Model

Thyrocare’s growth strategy centered on affordability and scale: at a time when competitors charged around ₹600 for a thyroid profile test, Thyrocare offered the same service for roughly ₹150, relying on a franchise-based collection model that allowed samples from across the country to be sent to a centralized lab in Mumbai for processing. 

This approach allowed the company to expand rapidly while keeping operational costs low, eventually growing to more than 1,000 outlets across India, Nepal, Bangladesh, and the Middle East, and processing hundreds of millions of samples over the company’s history.

Going Public and Personal Loss (2016)

Thyrocare listed on Indian stock exchanges in 2016, a major milestone in the company’s growth. The timing, however, was marked by profound personal tragedy: Velumani’s wife, Sumathi, was diagnosed with pancreatic cancer in October 2015 and passed away on February 13, 2016, roughly 100 days before the company’s IPO opened in May of that year. 

Velumani has spoken publicly and emotionally about this loss, describing his mother as the inspiration for his early success and his wife as the person without whom the company’s growth would not have been possible.

The PharmEasy Deal and a Public Investment Loss (2021–2024)

In June 2021, in one of the first instances of an Indian startup acquiring a listed company, Velumani sold his 66.1% stake in Thyrocare to API Holdings, the parent company of PharmEasy, for ₹4,546 crore. 

Of that amount, he reinvested ₹1,500 crore back into API Holdings itself, acquiring roughly a 5% stake in the company at what was then a $4 billion valuation. He explained the decision at the time by stating he saw greater long-term potential for Thyrocare under new ownership, remarking candidly that some considered him “mad for leaving the company.”

That reinvestment, however, did not go as planned. In February 2024, Velumani publicly disclosed on social media that he had lost roughly ₹1,400 crore on the investment, writing pointedly that he had been “greedy and blinded” as an investor — a striking admission from someone widely regarded as one of India’s most disciplined, frugality-focused entrepreneurs. 

He continues to lead Nueclear Healthcare Limited, his radiology diagnostics venture, as founder and managing director.

Personal Life

Dr. Velumani married Sumathi, daughter of J. K. Rao and Sarala Rao, in 1986, while he was still working at BARC. The couple had two children, Anand Velumani, born in 1989, and Amruta Velumani, born in 1991. 

Image Courtesy: velumani / Official Website (Arokiaswamy Velumani with his wife, Sumathi Velumani)

Sumathi passed away from pancreatic cancer in February 2016, a loss Velumani has continued to publicly honor; in November 2024, he marked what would have been their 38th wedding anniversary with a heartfelt social media post describing her as his co-founder and writing simply, “Miss You Darling.” 

He has not remarried and continues to speak openly about her role in Thyrocare’s success. Velumani is also known as an active public speaker and philanthropist, frequently sharing candid life and business lessons, including both his successes and his acknowledged setbacks, with aspiring entrepreneurs.

Frequently Asked Questions (FAQs)

What is Arokiaswamy Velumani’s Net Worth?

The net worth of Arokiaswamy Velumani is estimated to be more than ₹5,000 crore or $600 million, according to unconfirmed reports. It depends on the amount he received from selling his Thyrocare stake, his other business interests, and the rest of his assets.

How did Arokiaswamy Velumani make his money?

He co-founded Thyrocare Technologies in 1996 with around ₹1 lakh from his provident fund. He made one of the largest franchise models for thyroid tests and sold his 66.1% stake to PharmEasy’s parent company, API Holdings, for ₹4,546 crore in 2021, which eventually made him a billionaire.

How old is Arokiaswamy Velumani?

Arokiaswamy Velumani was born on April 12, 1959, in Tamil Nadu, India.

Who was Arokiaswamy Velumani’s wife?

Arokiaswamy Velumani’s wife, Sumathi, passed away due to pancreatic cancer in February 2016. She had been with him since 1986. Sumathi, also Thyrocare’s first employee and co-founder, has also contributed immensely to his success.

What was Arokiaswamy Velumani’s education?

Arokiaswamy Velumani studied at the University of Madras and earned his B.Sc. Thereafter, he went on to get his Master’s and Doctorate degrees in Biochemistry from Mumbai University.

Why did Arokiaswamy Velumani sell Thyrocare?

Arokiaswamy Velumani sold his 66.1% Thyrocare stake to PharmEasy’s parent company, API Holdings, for ₹4,546 crore in 2021. He mentioned that he thought the company would benefit under new management and that he may not be the best person to lead the organization.

Did Arokiaswamy Velumani lose money in Thyrocare?

Yes, Arokiaswamy Velumani lost nearly ₹1,400 crore on the amount he invested when he sold his stake in Thyrocare to API Holding. He further revealed that he had taken this decision to invest in another company, but he was “greedy and blinded”.

What is Nueclear Healthcare Limited?

Nueclear Healthcare Limited is a radiology diagnostics organization that was founded and is being run by Arokiaswamy Velumani. It is known for providing affordable cancer imaging services.

Was Arokiaswamy Velumani employed somewhere before starting Thyrocare?

Arokiaswamy Velumani worked for 14 years as a research scientist at the Bhabha Atomic Research Centre (BARC), where he studied and treated thyroid diseases before leaving to start Thyrocare in 1995.

Does Arokiaswamy Velumani have any children?

Arokiaswamy Velumani has two children, Anand Velumani and Amruta Velumani.

Conclusion

Dr. Arokiaswamy Velumani’s narrative is, without a doubt, an exception among India’s rising billionaire class. While many tend to keep their private life hushed, rarely do they talk about their failures and defeats in media appearances and interviews. 

From surviving his early years spent in poverty to spending 14 years studying at BARC, and then launching Thyrocare with his Provident Fund withdrawal, Dr. Velumani has come a long way. However, it seems that not even the most prominent personalities are immune to the devastating effects of losing billions of rupees overnight, as evidenced by his admission that he lost roughly ₹1,400 crore after selling Thyrocare. 

Dr. Velumani was also deeply affected when his wife and business partner Sumathi passed away shortly before Thyrocare went public, despite his best efforts to conceal his anguish. While his net worth is not officially documented, his achievements and disclosures regarding his wealth management provide us with valuable information.